MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis (MELT)

This study has been completed.
Ferring Arzneimittel GmbH
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
First received: June 7, 2011
Last updated: June 11, 2013
Last verified: June 2013
Desmopressin in treatment of nocturnal enuresis (bedwetting).

Nocturnal Enuresis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis With Special Focus on Patient Satisfaction

Resource links provided by NLM:

Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Assessment of patient and parent satisfaction [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of wet nights [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Assessment of drinking volume [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Assessment of urine volume [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Assessment of patient compliance [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Enrollment: 138
Study Start Date: June 2011
Study Completion Date: May 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Patients treated with orally disintegrating tablet
Patients treated with tablets


Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with primary nocturnal enuresis

Inclusion Criteria:

  • Treatment of primary nocturnal enuresis within an overall therapeutical concept, eg, in cases of failure of other non-medicinal therapies or with indication of a medicinal therapy caused by nocturnal ADH deficiency
  • The patients and their parents have been informed about the study and have given their written consent for participation.

Exclusion Criteria:

  • The prescription of Minirin® tablets / Minirin® orally disintegrating tablet (fast dissolving desmopressin) is contraindicated
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01368913

  Show 73 Study Locations
Sponsors and Collaborators
Ferring Pharmaceuticals
Ferring Arzneimittel GmbH
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01368913     History of Changes
Other Study ID Numbers: 000018 
Study First Received: June 7, 2011
Last Updated: June 11, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Nocturnal Enuresis
Behavioral Symptoms
Elimination Disorders
Mental Disorders
Urination Disorders
Urologic Diseases

ClinicalTrials.gov processed this record on May 26, 2016